IN2012DN00754A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN00754A IN2012DN00754A IN754DEN2012A IN2012DN00754A IN 2012DN00754 A IN2012DN00754 A IN 2012DN00754A IN 754DEN2012 A IN754DEN2012 A IN 754DEN2012A IN 2012DN00754 A IN2012DN00754 A IN 2012DN00754A
- Authority
- IN
- India
- Prior art keywords
- compounds
- antagonists
- lpa
- medicaments
- diseases
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000005557 antagonist Substances 0.000 abstract 2
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
- C07F9/653—Five-membered rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23128209P | 2009-08-04 | 2009-08-04 | |
| PCT/US2010/044284 WO2011017350A2 (en) | 2009-08-04 | 2010-08-03 | Compounds as lysophosphatidic acid receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN00754A true IN2012DN00754A (h) | 2015-06-19 |
Family
ID=43544907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN754DEN2012 IN2012DN00754A (h) | 2009-08-04 | 2010-08-03 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8592402B2 (h) |
| EP (1) | EP2462128B1 (h) |
| JP (1) | JP2013501064A (h) |
| CN (1) | CN102574822A (h) |
| IN (1) | IN2012DN00754A (h) |
| WO (1) | WO2011017350A2 (h) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010068775A2 (en) | 2008-12-11 | 2010-06-17 | Amira Pharmaceuticals, Inc. | Alkyne antagonists of lysophosphatidic acid receptors |
| GB2466121B (en) | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
| GB2470833B (en) | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
| CN102574822A (zh) | 2009-08-04 | 2012-07-11 | 阿米拉制药公司 | 作为溶血磷脂酸受体拮抗剂的化合物 |
| GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| CA2820817A1 (en) | 2010-12-07 | 2012-06-14 | Amira Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonists and uses thereof |
| EP2694496A1 (en) | 2011-04-05 | 2014-02-12 | Amira Pharmaceuticals, Inc. | 3- or 5 - bi phenyl - 4 - ylisoxazole - based compounds useful for the treatment of fibrosis, pain, cancer and respiratory, allergic, nervous system or cardiovascular disorders |
| WO2012138648A1 (en) * | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
| US8912202B2 (en) * | 2011-08-08 | 2014-12-16 | Merck Patent Gmbh | N-(benzimimdazol-2-yl)-cyclopropane carboxamides as lysophosphatidic acid antagonists |
| JP2014525932A (ja) * | 2011-08-15 | 2014-10-02 | インターミューン， インコーポレイテッド | リゾホスファチド酸レセプターアンタゴニスト |
| AU2012340698A1 (en) | 2011-11-22 | 2014-04-24 | Intermune, Inc. | Methods of diagnosing and treating idiopathic pulmonary fibrosis |
| CN104364239B (zh) | 2012-06-13 | 2017-08-25 | 霍夫曼-拉罗奇有限公司 | 二氮杂螺环烷烃和氮杂螺环烷烃 |
| MA37765A1 (fr) * | 2012-06-20 | 2017-04-28 | Hoffmann La Roche | Composés de pyrazole substitués utilisés comme antagonistes de lpar |
| HK1206331A1 (en) * | 2012-08-09 | 2016-01-08 | Neuropore Therapies, Inc. | Aryl-and heteroaryl-substituted benzene derivatives as modulators of pi3-kinase signalling pathways |
| BR112015004111A2 (pt) | 2012-09-25 | 2017-07-04 | Hoffmann La Roche | novos derivados bicíclicos |
| DK2940013T3 (en) | 2012-12-28 | 2018-03-26 | Ube Industries | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND |
| US20140213538A1 (en) * | 2013-01-15 | 2014-07-31 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| SG10201803833WA (en) * | 2013-03-15 | 2018-06-28 | Epigen Biosciences Inc | Heterocyclic compounds useful in the treatment of disease |
| EA038294B1 (ru) * | 2013-05-24 | 2021-08-05 | Эпиджен Байосайенсиз, Инк. | Гетероциклические соединения, применимые в лечении заболеваний |
| GB201314926D0 (en) | 2013-08-20 | 2013-10-02 | Takeda Pharmaceutical | Novel Compounds |
| EA201691044A1 (ru) | 2013-11-26 | 2016-09-30 | Ф. Хоффманн-Ля Рош Аг | Новый октагидро-циклобута[1,2-c;3,4-c']дипиррол-2-ил |
| EP3590939A1 (en) | 2014-03-26 | 2020-01-08 | F. Hoffmann-La Roche AG | Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
| WO2015144609A1 (en) | 2014-03-26 | 2015-10-01 | F. Hoffmann-La Roche Ag | Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
| AU2015240519B2 (en) | 2014-04-04 | 2019-08-15 | X-Rx, Inc. | Substituted spirocyclic inhibitors of autotaxin |
| WO2015175171A1 (en) * | 2014-04-23 | 2015-11-19 | X-Rx Discovery, Inc. | Substituted n-(2-(amino)-2-oxoethyl)benzamide inhibitors of autotaxin and their preparation and use in the treatment of lpa-dependent or lpa-mediated diseases |
| CA2953472C (en) | 2014-06-27 | 2022-08-02 | Ube Industries, Ltd. | Halogen-substituted heterocyclic compound salt |
| WO2016046782A1 (en) * | 2014-09-26 | 2016-03-31 | Glenmark Pharmaceuticals S.A. | Imidazole biaryl compounds as s-nitrosoglutathione reductase inhibitors |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| CN113651873B (zh) | 2015-05-01 | 2025-09-02 | Onl医疗股份有限公司 | 肽组合物和使用方法 |
| CA2988306A1 (en) | 2015-06-05 | 2016-12-08 | Vertex Pharmaceuticals Incorporated | Triazoles for the treatment of demyelinating diseases |
| MX377277B (es) | 2015-09-04 | 2025-03-07 | Hoffmann La Roche | Derivados de fenoximetilo. |
| RU2018114289A (ru) | 2015-09-24 | 2019-10-24 | Ф. Хоффманн-Ля Рош Аг | Бициклические соединения в качестве ингибиторов аутотаксина (atx) |
| RU2018112230A (ru) | 2015-09-24 | 2019-10-30 | Ф. Хоффманн-Ля Рош Аг | Бициклические соединения в качестве ингибиторов atx |
| WO2017050747A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | New bicyclic compounds as dual atx/ca inhibitors |
| JP6877413B2 (ja) | 2015-09-24 | 2021-05-26 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 二重ａｔｘ／ｃａ阻害剤としての新規な二環式化合物 |
| WO2018106643A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Heterocyclic azoles for the treatment of demyelinating diseases |
| WO2018106641A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Pyrazoles for the treatment of demyelinating diseases |
| WO2018106646A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Aminotriazoles for the treatment of demyelinating diseases |
| EP3596060B1 (en) | 2017-03-16 | 2023-09-20 | F. Hoffmann-La Roche AG | New bicyclic compounds as atx inhibitors |
| BR112019019017A2 (pt) | 2017-03-16 | 2020-04-14 | Hoffmann La Roche | compostos heterocíclicos de utilidade como inibidores duplos de atx/ca |
| MX2020004202A (es) | 2017-10-30 | 2020-08-13 | Neuropore Therapies Inc | Fenil sulfonil fenil triazol tionas sustituidas y usos de las mismas. |
| US11261174B2 (en) | 2017-12-19 | 2022-03-01 | Bristol-Myers Squibb Company | Pyrazole O-linked carbamoyl cyclohexyl acids as LPA antagonists |
| US11447475B2 (en) | 2017-12-19 | 2022-09-20 | Bristol-Myers Squibb Company | Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists |
| US11319309B2 (en) | 2017-12-19 | 2022-05-03 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azines as LPA antagonists |
| CA3085938A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid triazole azoles as lpa antagonists |
| JP7299892B2 (ja) * | 2017-12-19 | 2023-06-28 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのシクロヘキシル酸ピラゾールアジン |
| ES2925626T3 (es) * | 2017-12-19 | 2022-10-19 | Bristol Myers Squibb Co | Acidos isoxazol-O-carbamoilciclohexílicos como antagonistas de LPA |
| CN112074515B (zh) * | 2017-12-19 | 2025-01-10 | 百时美施贵宝公司 | 作为lpa拮抗剂的环己基酸异噁唑唑类 |
| WO2019126103A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid pyrazole azoles as lpa antagonists |
| EP3710438B1 (en) | 2017-12-19 | 2021-10-20 | Bristol-Myers Squibb Company | Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
| BR112020011953A2 (pt) | 2017-12-19 | 2020-11-17 | Bristol-Myers Squibb Company | ácidos carbamoil ciclo-hexílicos n-ligados a pirazol como antagonistas de lpa |
| CN112055711B (zh) | 2017-12-19 | 2024-07-23 | 百时美施贵宝公司 | 作为lpa拮抗剂的环己基酸三唑吖嗪类 |
| EP3852746B1 (en) | 2018-09-18 | 2023-03-29 | Bristol-Myers Squibb Company | Cyclopentyl acids as lpa antagonists |
| KR102788997B1 (ko) | 2018-09-18 | 2025-03-28 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 옥사비시클로 산 |
| WO2020257135A1 (en) | 2019-06-18 | 2020-12-24 | Bristol-Myers Squibb Company | Triazole carboxylic acids as lpa antagonists |
| CN114599640A (zh) * | 2019-06-18 | 2022-06-07 | 百时美施贵宝公司 | 作为lpa拮抗剂的异噁唑羧酸 |
| CN114599641A (zh) | 2019-06-18 | 2022-06-07 | 百时美施贵宝公司 | 作为lpa拮抗剂的环丁基羧酸 |
| US12338203B2 (en) * | 2019-07-30 | 2025-06-24 | Taisho Pharmaceutical Co., Ltd. | Urea compound for antagonizing LPA1 receptor |
| KR102775995B1 (ko) | 2019-11-15 | 2025-03-11 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제로서의 트라이아졸 카르바메이트 피리딜 설폰아미드 및 이의 용도 |
| EP4161936A1 (en) | 2020-06-03 | 2023-04-12 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| TWI843503B (zh) | 2020-06-03 | 2024-05-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| US12383547B2 (en) | 2020-07-01 | 2025-08-12 | Vanderbilt University | Methods of treatment for a kidney disease |
| CN115989220A (zh) * | 2020-07-16 | 2023-04-18 | 奇斯药制品公司 | 作为lpa受体抑制剂的酰氨基环己烷酸衍生物 |
| CN117295717A (zh) | 2021-05-11 | 2023-12-26 | 吉利德科学公司 | Lpa受体拮抗剂及其用途 |
| AU2022405082B2 (en) | 2021-12-08 | 2025-09-25 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
| US5116817A (en) | 1982-12-10 | 1992-05-26 | Syntex (U.S.A.) Inc. | LHRH preparations for intranasal administration |
| US4476116A (en) | 1982-12-10 | 1984-10-09 | Syntex (U.S.A.) Inc. | Polypeptides/chelating agent nasal compositions having enhanced peptide absorption |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US5011692A (en) | 1985-12-28 | 1991-04-30 | Sumitomo Pharmaceuticals Company, Limited | Sustained pulsewise release pharmaceutical preparation |
| US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
| US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
| US5017381A (en) | 1990-05-02 | 1991-05-21 | Alza Corporation | Multi-unit pulsatile delivery system |
| US5229135A (en) | 1991-11-22 | 1993-07-20 | Prographarm Laboratories | Sustained release diltiazem formulation |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| GB9523946D0 (en) | 1995-11-23 | 1996-01-24 | Bayer Ag | Leukotriene antagonistic benzoic acid derivatives |
| US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
| CA2276034A1 (en) | 1996-12-23 | 1998-07-02 | Mimi Lifen Quan | Oxygen or sulfur containing 5-membered heteroaromatics as factor xa inhibitors |
| JP3237608B2 (ja) | 1997-04-21 | 2001-12-10 | 住友製薬株式会社 | イソキサゾール誘導体 |
| US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
| US6391452B1 (en) | 1997-07-18 | 2002-05-21 | Bayer Corporation | Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations |
| WO2000059902A2 (en) | 1999-04-02 | 2000-10-12 | Du Pont Pharmaceuticals Company | Aryl sulfonyls as factor xa inhibitors |
| ATE420878T1 (de) * | 2000-02-18 | 2009-01-15 | Kyowa Hakko Kirin Co Ltd | Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente |
| AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
| DE60234318D1 (de) | 2001-02-08 | 2009-12-24 | Ono Pharmaceutical Co | Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors |
| US7521192B2 (en) | 2001-04-18 | 2009-04-21 | Rigel Pharmaceuticals, Inc. | EDG: modulators of lymphocyte activation and migration |
| WO2003007991A1 (en) | 2001-07-17 | 2003-01-30 | Ono Pharmaceutical Co., Ltd. | Pancreatic juice secretion regulators comprising lpa receptor controller |
| MY151199A (en) | 2001-11-02 | 2014-04-30 | Rigel Pharmaceuticals Inc | Substituted diphenyl heterocycles useful for treating hcv infection |
| JP4569106B2 (ja) | 2001-12-25 | 2010-10-27 | 味の素株式会社 | 臓器線維化抑制剤 |
| US20050261298A1 (en) | 2002-01-18 | 2005-11-24 | David Solow-Cordero | Methods of treating conditions associated with an Edg-7 receptor |
| US20050101518A1 (en) | 2002-01-18 | 2005-05-12 | David Solow-Cordero | Methods of treating conditions associated with an EDG-2 receptor |
| US20050113283A1 (en) | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
| JP2005519915A (ja) | 2002-01-18 | 2005-07-07 | セレテック・リミテッド・ライアビリティ・カンパニー | Ｅｄｇ受容体に関連する症状の処置方法 |
| US20040014662A1 (en) | 2002-05-08 | 2004-01-22 | Per Lindquist | Modulation of neural stem cells and neural progenitor cells |
| CA2484233A1 (en) | 2002-05-13 | 2003-11-27 | Eli Lilly And Company | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes |
| JP4596314B2 (ja) | 2002-05-28 | 2010-12-08 | 小野薬品工業株式会社 | β−アラニン誘導体およびその用途 |
| AU2003241834A1 (en) | 2002-06-26 | 2004-01-19 | Ono Pharmaceutical Co., Ltd. | Remedy for chronic disease |
| JP4691988B2 (ja) | 2002-10-03 | 2011-06-01 | 小野薬品工業株式会社 | Ｌｐａ受容体拮抗剤 |
| AU2003294315A1 (en) | 2002-11-19 | 2004-06-15 | Amgen Inc. | Amplified genes involved in cancer |
| US20040192739A1 (en) | 2003-01-16 | 2004-09-30 | David Solow-Cordero | Methods of treating conditions associated with an Edg-2 receptor |
| US20040167132A1 (en) | 2003-01-16 | 2004-08-26 | Geetha Shankar | Methods of treating conditions associted with an Edg-2 receptor |
| US20050065194A1 (en) | 2003-01-16 | 2005-03-24 | Geetha Shankar | Methods of treating conditions associated with an Edg-2 receptor |
| US7135469B2 (en) | 2003-03-18 | 2006-11-14 | Bristol Myers Squibb, Co. | Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors |
| US7115642B2 (en) | 2003-05-02 | 2006-10-03 | Rigel Pharmaceuticals, Inc. | Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating HCV infection |
| ES2379169T3 (es) | 2003-05-19 | 2012-04-23 | Irm Llc | Composiciones y compuestos inmunosupresores |
| WO2005012269A1 (ja) | 2003-08-05 | 2005-02-10 | Ajinomoto Co., Inc. | 新規アゾール化合物 |
| WO2005058790A1 (ja) | 2003-12-19 | 2005-06-30 | Ono Pharmaceutical Co., Ltd. | リゾホスファチジン酸受容体拮抗作用を有する化合物およびその用途 |
| DE10360369A1 (de) | 2003-12-22 | 2005-07-14 | Bayer Cropscience Ag | Amide |
| JP2006096712A (ja) | 2004-09-30 | 2006-04-13 | Senju Pharmaceut Co Ltd | Ｌｐａ受容体拮抗剤を含有する角膜知覚改善剤 |
| AR055041A1 (es) | 2005-03-23 | 2007-08-01 | Merck Frosst Canada Ltd | Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas. |
| US20080306124A1 (en) | 2005-06-08 | 2008-12-11 | Rainer Albert | Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands |
| WO2007007588A1 (ja) | 2005-07-08 | 2007-01-18 | Ono Pharmaceutical Co., Ltd. | 平面性を有する環状基を母核とする化合物 |
| CA2618586A1 (en) | 2005-08-11 | 2007-02-15 | Merck Frosst Canada Ltd. | Novel substituted 1,2,3-triazolylmethyl-benzothiophene or -indole and their use as leukotriene biosynthesis inhibitors |
| WO2007024922A1 (en) | 2005-08-23 | 2007-03-01 | Irm Llc | Immunosuppressant compounds and compositions |
| US7405302B2 (en) | 2005-10-11 | 2008-07-29 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| US20070225285A1 (en) | 2005-11-04 | 2007-09-27 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
| US20070219206A1 (en) | 2005-11-04 | 2007-09-20 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| CA2636043A1 (en) | 2006-01-23 | 2007-08-02 | Amira Pharmaceuticals, Inc. | Tricyclic inhibitors of 5-lipoxygenase |
| WO2007096647A2 (en) | 2006-02-27 | 2007-08-30 | Sterix Limited | Diaryl compounds as non-steroidal inhibitors of 17-beta hydroxysteroid dehydrogenase and/or steroid sulphatase for the treatment of oestrogen-related diseases such as hormone dependent breast cancer |
| US20090029949A1 (en) | 2006-05-25 | 2009-01-29 | Parrill-Baker Abby L | GPCR Ligands Identified by Computational Modeling |
| US20080051372A1 (en) | 2006-08-24 | 2008-02-28 | The Scripps Research Institute | Methods utilizing cell-signaling lysophospholipids |
| WO2008024979A2 (en) | 2006-08-24 | 2008-02-28 | The Scripps Research Institute | Methods utilizing cell-signaling lysophospholipids |
| WO2008112201A2 (en) | 2007-03-12 | 2008-09-18 | The General Hospital Corporation | Lysophosphatidic acid receptor targeting for lung disease |
| US9163091B2 (en) | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
| WO2009011850A2 (en) | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Novel therapeutic compounds |
| SG190620A1 (en) | 2008-05-05 | 2013-06-28 | Sanofi Aventis | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals |
| WO2010068775A2 (en) | 2008-12-11 | 2010-06-17 | Amira Pharmaceuticals, Inc. | Alkyne antagonists of lysophosphatidic acid receptors |
| GB2466121B (en) | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
| GB2470833B (en) | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
| CN102574822A (zh) | 2009-08-04 | 2012-07-11 | 阿米拉制药公司 | 作为溶血磷脂酸受体拮抗剂的化合物 |
| GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
-
2010
- 2010-08-03 CN CN2010800429638A patent/CN102574822A/zh active Pending
- 2010-08-03 JP JP2012523709A patent/JP2013501064A/ja active Pending
- 2010-08-03 US US13/388,502 patent/US8592402B2/en active Active
- 2010-08-03 IN IN754DEN2012 patent/IN2012DN00754A/en unknown
- 2010-08-03 WO PCT/US2010/044284 patent/WO2011017350A2/en not_active Ceased
- 2010-08-03 EP EP10807045.9A patent/EP2462128B1/en not_active Not-in-force
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013501064A (ja) | 2013-01-10 |
| EP2462128B1 (en) | 2016-09-21 |
| CN102574822A (zh) | 2012-07-11 |
| US20120196839A1 (en) | 2012-08-02 |
| WO2011017350A2 (en) | 2011-02-10 |
| EP2462128A4 (en) | 2012-10-03 |
| EP2462128A2 (en) | 2012-06-13 |
| WO2011017350A3 (en) | 2011-06-30 |
| US8592402B2 (en) | 2013-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN02735A (h) | ||
| IN2012DN02702A (h) | ||
| IN2012DN00754A (h) | ||
| PH12013501136A1 (en) | Lysophosphatidic acid receptor antagonists and uses thereof | |
| MY163055A (en) | Polycyclic antagonists of lysophosphatidic acid receptors | |
| WO2010077883A3 (en) | Antagonists of lysophosphatidic acid receptors | |
| PH12020550450A1 (en) | Certain chemical entities, compositions and methods | |
| PH12015501737A1 (en) | Androgen receptor modulators and uses thereof | |
| PH12013500481A1 (en) | Estrogen receptor modulators and uses thereof | |
| PH12012502419A1 (en) | Estrogen receptor modulators and uses thereof | |
| WO2010068775A3 (en) | Alkyne antagonists of lysophosphatidic acid receptors | |
| PH12014501351A1 (en) | Fluorinated estrogen receptor modulators and uses thereof | |
| PH12014502095A1 (en) | Estrogen receptor modulators and uses thereof | |
| WO2012024620A3 (en) | Autotaxin inhibitors and uses thereof | |
| UA98839C2 (en) | N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors | |
| IN2012DN02471A (h) | ||
| TN2010000463A1 (en) | Compositions and methods for preparing and using same |